[Update on neuromeningeal cryptococcosis in Dakar].

This study was carried out to provide current information on neuromeningeal cryptococcosis at the Infectious Diseases Clinic in Fann Teaching Hospital in Dakar. Epidemiological, clinical, biological and therapeutic data were collected retrospectively from files of patients treated between 1999 and 2003. A total of 45 cases including 34 in HIV-positive patients were analyzed. The prevalence of neuronieningeal cryptococcosis in H1V-infected patients was 2.9% in 2000 and, 7.9% in 2003. Only 6 patients had been using antiretroviral therapy. The male-to-female sex ratio was 2 and mean age was 34 years (range, 18-61 years). Clinical presentation involved fever (73.3%), persistent headache (86.7%), vomiting (66.7%), meningeal syndrome (60%), coma (20%), convulsion (13.3%), focal neurological deficit (15.6%), and cranial nerve dysfunction (11.1 %). The CD4-cell count was less than 200/mm3 in 14 of 15 patients tested. Cerebrospinal fluid was clear in most cases (88.9%) and lytuphocytic in half (52%) with a mean albumin concentration of 0.79 g/l. Positive results were obtained with India ink smears in 35 of 45 cases, cultures in 30 of 31 cases and cryptococcic antigen detection in CSF in 9 of 9 cases. The most frequently used antifungal drug was fiuconazole (93%). The mortality rate was 71.1% (32 deaths) overall and reached 78.9% in patients with less than 20 cells/mmm3 in CSF (78.9%). Three measures are necessary for control of neuromeningeal crytococcosis: routine screening in severely immunodeficient HIV patients, distribution of effective systemic antifungal drugs and primary prevention by widespread use of antiretroviral therapy.